Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-22

Clinical Trial Update: Safety and Immunogenicity of a Chlamydia Vaccine CTH522 [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing the safety and immunogenicity of the Chlamydia vaccine CTH522 for Trachoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CTH522 vaccine (CTH522)

Snippet

Sponsor: Statens Serum Institut | Conditions: Trachoma | Phase 1 | Status: COMPLETED | Results posted: 2024-08-22